Last reviewed · How we verify
NCT04989309
Left and Right Hemisphere Contributions to Speech Perception
NA trial testing Transcranial Magnetic Stimulation in Neural Bases of Speech Perception in 26 participants. Enrolling by invitation.
31 December 2025
Quick facts
| Lead sponsor | University of Connecticut |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 26 |
| Start date | 19 December 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transcranial Magnetic Stimulation — full drug profile →
Conditions studied
- Neural Bases of Speech Perception — all drugs for Neural Bases of Speech Perception →
Sponsor
University of Connecticut
Who can join
18 and older, any sex, with Neural Bases of Speech Perception. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Left and right temporal brain areas are thought to contribute to speech perception, but the division of labor between left and right hemisphere regions is still unclear. Here we use transcranial magnetic stimulation (TMS) to stimulate left and right temporal foci and a vertex control site to temporarily disrupt activation at the stimulation site, using a "virtual lesion" approach to test the effect of stimulation site on a series of speech perception tasks. This portion of the project is basic research. However, since TMS is viewed as an intervention, studies involving TMS in this grant are considered clinical trials.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04989309
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial Magnetic Stimulation
Trials testing the same drug.
- NCT07526285 — Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for Treatment of Post-Traumatic Stress Disorder (PTSD) · NA · not yet recruiting
- NCT07050862 — rTMS for Tobacco Use in Veterans · NA · not yet recruiting
- NCT07145866 — Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) · Phase 4 · not yet recruiting
- NCT07516028 — Brain Connectivity and Corticospinal Excitability in Response to Moderate Hypoxia · NA · not yet recruiting
- NCT07389694 — Using Transcranial Magnetic Stimulation to Treat Stuttering · NA · recruiting
Other University of Connecticut trials
Trials by the same sponsor.
- NCT06794840 — JomCare Study - A Harm Reduction Study · NA · not yet recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT06381921 — Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain · NA · recruiting
- NCT06393725 — Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions · NA · recruiting
- NCT06579027 — A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04989309 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Connecticut
- Last refreshed: 15 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04989309.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing